| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. | N Engl J Med | 2013 | 18.08 |
| 2 | Targeting mitochondrial biogenesis to overcome drug resistance to MAPK inhibitors. | J Clin Invest | 2016 | 0.93 |
| 3 | Proteomic characterization of non-small cell lung cancer in a comprehensive translational thoracic oncology database. | J Clin Bioinforma | 2011 | 0.86 |
| 4 | Vemurafenib-induced interface dermatitis manifesting as radiation-recall and a keratosis pilaris-like eruption. | J Cutan Pathol | 2014 | 0.75 |
| 5 | Template for Reporting Results of Biomarker Testing of Specimens From Patients With Melanoma. | Arch Pathol Lab Med | 2015 | 0.75 |